Business Context and Reporting Period
This Form 8-K was filed by Savara Inc. (formerly Mast Therapeutics, Inc.) on May 1, 2017. The report details the filing of a prospectus supplement with the SEC in connection with an ongoing equity offering under an existing Form S-3 Registration Statement.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the aggregate offering price of up to $18.0 million for shares of common stock under a Common Stock Sales Agreement with H.C. Wainwright & Co., LLC.
Material Changes
The material event reported is the execution of a prospectus supplement on May 1, 2017, following the initial entry into the Sales Agreement on April 28, 2017. This action facilitates the "at-the-market" offering of the company's common stock.
Guidance, Outlook, and Risks
Management commentary is limited to the procedural status of the offering. The filing includes a standard disclaimer stating that the report does not constitute an offer to sell or a solicitation of an offer to buy shares in any jurisdiction where such an offer would be unlawful prior to registration. No specific forward-looking guidance or risk factors beyond standard securities law disclaimers are detailed in this specific text.
Investor Verification Checklist
- Verify the terms of the Common Stock Sales Agreement filed on April 28, 2017, referenced in Item 8.01.
- Review the full prospectus supplement filed on May 1, 2017, under Registration Statement File No. 333-202960.
- Confirm the legal opinion issued by Wilson Sonsini Goodrich & Rosati P.C. attached as Exhibit 5.1.
- Monitor the actual volume of shares sold and proceeds raised under the $18.0 million cap in subsequent filings.